Form 4: Vor Biopharma Inc. Executive Eyal C. Attar Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reports a transaction involving the withholding of common stock to cover tax obligations related to the settlement of restricted stock units.
Summary
- On November 6, 2024, Eyal C. Attar, the Chief Medical Officer of Vor Biopharma Inc., had 999 shares of common stock withheld to satisfy tax obligations.
- The shares were withheld in connection with the settlement of restricted stock units.
- Following the transaction, Attar directly owns 91,773 shares of Vor Biopharma Inc. common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a standard transaction related to tax obligations. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track changes in ownership and potential alignment of interests between management and shareholders.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine adjustment of share ownership due to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 11/06/2024 | Date of transaction: 999 shares of common stock withheld for tax obligations. |
| 11/08/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.